Metropolitan Life Insurance Company (MetLife)’s Spark Therapeutics, Inc. Common Stock ONCE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-11,128
| Closed | -$1.08M | – | 2597 |
|
|
2019
Q3 | $1.08M | Buy |
11,128
+729
| +7% | +$73K | 0.02% | 817 |
|
|
2019
Q2 | $1.06M | Buy |
10,399
+192
| +2% | +$20.7K | 0.02% | 860 |
|
|
2019
Q1 | $1.16M | Hold |
10,207
| – | – | 0.02% | 807 |
|
|
2018
Q4 | $400K | Hold |
10,207
| – | – | 0.01% | 1342 |
|
|
2018
Q3 | $557K | Hold |
10,207
| – | – | 0.01% | 1283 |
|
|
2018
Q2 | $845K | Buy |
10,207
+1,180
| +13% | +$91.1K | 0.01% | 1005 |
|
|
2018
Q1 | $601K | Buy |
9,027
+202
| +2% | +$11.7K | 0.01% | 1159 |
|
|
2017
Q4 | $454K | Sell |
8,825
-9,415
| -52% | -$676K | 0.01% | 1355 |
|
|
2017
Q3 | $1.63M | Buy |
18,240
+2,299
| +14% | +$175K | 0.01% | 1014 |
|
|
2017
Q2 | $952K | Buy |
15,941
+2,093
| +15% | +$117K | 0.01% | 1268 |
|
|
2017
Q1 | $739K | Hold |
13,848
| – | – | 0.01% | 1399 |
|
|
2016
Q4 | $691K | Hold |
13,848
| – | – | 0.01% | 1538 |
|
|
2016
Q3 | $832K | Buy |
13,848
+1,070
| +8% | +$61.7K | 0.01% | 1387 |
|
|
2016
Q2 | $653K | Buy |
12,778
+4,955
| +63% | +$212K | ﹤0.01% | 1530 |
|
|
2016
Q1 | $231K | Buy |
7,823
+2,465
| +46% | +$77.8K | ﹤0.01% | 2088 |
|
|
2015
Q4 | $243K | Hold |
5,358
| – | – | ﹤0.01% | 2108 |
|
|
2015
Q3 | $224K | Sell |
5,358
-1,719
| -24% | -$89.7K | ﹤0.01% | 2213 |
|
|
2015
Q2 | $427K | Buy |
+7,077
| New | +$468K | ﹤0.01% | 1852 |
|
Metropolitan Life Insurance Company (MetLife)'s ONCE Position: Q4 2019 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Spark Therapeutics, Inc. Common Stock (ONCE) in Q4 2019, closing a stake of 11,128 shares — an estimated $1.08M sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in ONCE in Q2 2015 and held it in 18 quarters. The position peaked at $1.63M in Q3 2017. 0 funds tracked by Wall St. Rank hold ONCE as of Q4 2019.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Spark Therapeutics, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 11,128 Spark Therapeutics, Inc. Common Stock shares in Q4 2019, an estimated $1.08M.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Spark Therapeutics, Inc. Common Stock in Q2 2015 and held it in 18 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Spark Therapeutics, Inc. Common Stock position peaked at $1.63M in Q3 2017.
- 0 funds tracked by Wall St. Rank held Spark Therapeutics, Inc. Common Stock as of Q4 2019.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q4 2019, filed 14 Feb 2020.